目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT OF RECESSION ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICE ANALYSIS, BY SERVICE
5.4.2 INDICATIVE PRICE ANALYSIS, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 SINGLE-USE BIOPROCESSING SYSTEMS
5.7.1.2 CONTINUOUS MANUFACTURING
5.7.1.3 ADVANCED FORMULATION TECHNOLOGIES
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 HPLC
5.7.2.2 MASS SPECTROMETRY
5.7.2.3 NGS
5.7.2.4 AUTOMATION & ROBOTICS
5.7.2.5 PROCESS ANALYTICAL TECHNOLOGY
5.7.3 ADJCENT TECHNOLOGY
5.7.3.1 3D PRINTING
5.7.3.2 ARTIFICIAL INTELLIGENCE & MACHINE LEARNING
5.8 KEY CONFERENCES & EVENTS 2024-2025
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY SCENARIO
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.10 PORTER’S FIVE FORCES’ ANALYSIS
5.11 INVESTMENT AND FUNDING SCENARIO
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 ANDA APPROVALS (2019-2023)

6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
6.1 INTRODUCTION
6.2 PHARMACEUTICAL MANUFACTURING SERVICES
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
6.2.2.1 Parenteral/Injectable manufacturing services
6.2.2.2 Tablet manufacturing services
6.2.2.3 Capsule manufacturing services
6.2.2.4 Oral liquid manufacturing services
6.2.2.5 Semi-solid manufacturing services
6.2.2.6 Other formulations manufacturing services
Note 1: Other formulations manufacturing services segment include topicals, ophthalmic, inhalational, and powders, etc.
6.3 DRUG DEVELOPMENT SERVICES
6.4 BIOLOGICS MANUFACTURING SERVICES
6.4.1 BIOLOGICS API MANUFACTURING SERVICES
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
Note 2: Tentative segmentation, subject to minor revision as research progresses.

7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE
7.1 INTRODUCTION
7.2 MANUFACTURING SERVICES
7.3 PACKAGING & LABELLING SERVICES
7.4 FILL-FINISH SERVICES
7.5 SUPPLY CHAIN SERVICES
7.6 OTHER SERVICES
Note 3: Other services segment include analytical testing, quality control services, etc.

8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
8.1 INTRODUCTION
8.2 BIG PHARMACEUTICAL COMPANIES
8.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
8.4 GENERIC PHARMACEUTICAL COMPANIES
8.5 OTHER END USERS
Note 4: Other end users segment includes CROs, academic institutes.

9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.2.3 RECESSION IMPACT
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 SWITZERLAND
9.3.7 POLAND
9.3.8 REST OF EUROPE
9.3.9 RECESSION IMPACT
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 SOUTH KOREA
9.4.4 INDIA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA PACIFIC
9.4.7 RECESSION IMPACT
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.2 MEXICO
9.5.3 REST OF LATIN AMERICA
9.5.4 RECESSION IMPACT
9.6 MIDDLE EAST
9.6.1 GCC COUNTRIES
9.6.1.1 SAUDI ARABIA (KSA)
9.6.1.2 UNITED ARAB EMIRATES (UAE)
9.6.1.3 REST OF GCC COUNTRIES
9.6.2 REST OF MIDDLE EAST
9.6.3 RECESSION IMPACT
9.7 AFRICA
9.7.1 RECESSION IMPACT
Note 5: Rest of Europe includes Russia, Portugal, Poland, Netherlands, Finland, Belgium, Austria, Hungary, Iceland, Ireland, Norway, and Luxembourg, among others
Note 6: Rest of Asia Pacific Includes Bangladesh, Bhutan, Nepal, Sri Lanka, Philippines, Singapore, Vietnam, Thailand, Taiwan, Cambodia, and IIndonesia among others
Note 7: Rest of Latin America Includes Colombia, Ecuador, Peru, Uruguay, Cuba and Chile
Note 8: GCC Includes Saudi Arabia, Uae, Bahrain, Kuwait, Qatar and Oman
Note 9: Rest of Middle East Includes Iran, Iraq, Israel, Jordan, Qatar, Yemen, and other countries.

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATERGIES/RIGHT TO WIN
10.3 REVENUE ANALYSIS, 2021-2023
10.4 MARKET SHARE ANALYSIS, 2023
10.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.5.1 BRAND/SERVICE COMPARATIVE ANALYSIS
10.6 COMPANY EVALUATION MATRIX:KEY PLAYERS, 2023
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
10.6.5 COMPANY FOOTPRINT:KEY PLAYERS, 2023
10.6.5.1 COMPANY FOOTPRINT
10.6.5.2 REGION FOOTPRINT
10.6.5.3 SERVICE FOOTPRINT
10.6.5.4 END USER FOOTPRINT
10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.7.1 PROGRESSIVE COMPANIES
10.7.2 RESPONSIVE COMPANIES
10.7.3 DYNAMIC COMPANIES
10.7.4 STARTING BLOCKS
10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.7.5.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY STARTUPS/SMES
10.7.5.2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
10.8 VALUATION AND FINANCIAL METRICS OF KEY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET PLAYERS
10.9 COMPETITIVE SCENARIO AND TRENDS

11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, Mnm View)*
11.1 KEY PLAYERS
11.1.1 LONZA GROUP
11.1.2 THERMO FISHER SCIENTIFIC
11.1.3 CATALENT (NOVO NORDISK)
11.1.4 RECIPHARM AB
11.1.5 ABBVIE, INC.
11.1.6 SEIGFRIED HOLDING AG
11.1.7 EVONIK INDUSTRIES
11.1.8 EUROFINS SCIENTIFIC
11.1.9 BOEHRINGER INGELHEIM
11.1.10 PIRAMAL PHARMA SOLUTIONS
11.1.11 SAMSUNG BIOLOGICS
11.1.12 WUXI APPTEC (WUXI STA)
11.1.13 FUJIFILM HOLDINGS CORPORATION
11.1.14 ALMAC GROUP
11.1.15 VETTER PHARMA
11.2 OTHER PLAYERS
11.2.1 DELPHARM HOLDINGS
11.2.2 YUHAN CORPORATION
11.2.3 CURIA GLOBAL INC.
11.2.4 CHARLES RIVER LABORATORIES
11.2.5 LANNETT COMPAN
11.2.6 CAMBREX CORPORATION
11.2.7 FAMAR HEALTHCARE SERVICES
11.2.8 SYNGENE (BIOCON)
11.2.9 SAI LIFE SCIENCES LTD
11.2.10 PCI PHARMA SERVICES